BRIEF-ImmunityBio: Median Overall Survival Unreached, Lymphopenia Reversed In Recurrent Glioblastoma On Anktiva And CAR-NK Chemo-Free Therapy

Reuters01-23

Jan 23 (Reuters) - Immunitybio Inc IBRX.O:

IMMUNITYBIO REPORTS MEDIAN OVERALL SURVIVAL NOT YET REACHED AND LYMPHOPENIA REVERSED IN RECURRENT GLIOBLASTOMA PATIENTS RECEIVING ANKTIVA® PLUS CAR-NK, CHEMO-FREE THERAPY
IMMUNITYBIO INC: THREE PARTICIPANTS EXPERIENCED SERIOUS ADVERSE EVENTS SUSPECTED TO BE RELATED TO EXPERIMENTAL THERAPY
IMMUNITYBIO INC: TREATMENT REGIMEN DEMONSTRATED A MANAGEABLE SAFETY PROFILE

Source text: ID:nBw95Lpc6a

Further company coverage: IBRX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2605785472?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-23 20:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605785472","market":"fut","top_or_hot":-1,"title":"BRIEF-ImmunityBio: Median Overall Survival Unreached, Lymphopenia Reversed In Recurrent Glioblastoma On Anktiva And CAR-NK Chemo-Free Therapy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-ImmunityBio: Median Overall Survival Unreached, Lymphopenia Reversed In Recurrent Glioblastoma On Anktiva And CAR-NK Chemo-Free Therapy</title></head><body><p><span>Jan 23 (Reuters)</span><span> - </span>Immunitybio Inc <span>IBRX.O</span>:</p><ul><li><p>IMMUNITYBIO REPORTS MEDIAN OVERALL SURVIVAL NOT YET REACHED AND LYMPHOPENIA REVERSED IN RECURRENT GLIOBLASTOMA PATIENTS RECEIVING ANKTIVA® PLUS CAR-NK, CHEMO-FREE THERAPY</p></li><li><p>IMMUNITYBIO INC: THREE PARTICIPANTS EXPERIENCED SERIOUS ADVERSE EVENTS SUSPECTED TO BE RELATED TO EXPERIMENTAL THERAPY</p></li><li><p>IMMUNITYBIO INC: TREATMENT REGIMEN DEMONSTRATED A MANAGEABLE SAFETY PROFILE</p></li></ul><p>Source text: <span>ID:nBw95Lpc6a</span></p><p>Further company coverage: <span>IBRX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-ImmunityBio: Median Overall Survival Unreached, Lymphopenia Reversed In Recurrent Glioblastoma On Anktiva And CAR-NK Chemo-Free Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-ImmunityBio: Median Overall Survival Unreached, Lymphopenia Reversed In Recurrent Glioblastoma On Anktiva And CAR-NK Chemo-Free Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-23 20:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-ImmunityBio: Median Overall Survival Unreached, Lymphopenia Reversed In Recurrent Glioblastoma On Anktiva And CAR-NK Chemo-Free Therapy</title></head><body><p><span>Jan 23 (Reuters)</span><span> - </span>Immunitybio Inc <span>IBRX.O</span>:</p><ul><li><p>IMMUNITYBIO REPORTS MEDIAN OVERALL SURVIVAL NOT YET REACHED AND LYMPHOPENIA REVERSED IN RECURRENT GLIOBLASTOMA PATIENTS RECEIVING ANKTIVA® PLUS CAR-NK, CHEMO-FREE THERAPY</p></li><li><p>IMMUNITYBIO INC: THREE PARTICIPANTS EXPERIENCED SERIOUS ADVERSE EVENTS SUSPECTED TO BE RELATED TO EXPERIMENTAL THERAPY</p></li><li><p>IMMUNITYBIO INC: TREATMENT REGIMEN DEMONSTRATED A MANAGEABLE SAFETY PROFILE</p></li></ul><p>Source text: <span>ID:nBw95Lpc6a</span></p><p>Further company coverage: <span>IBRX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260123:nTUA9B2XYV:1","article_id":"2605785472","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605785472","pubTimestamp":1769170190,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-ImmunityBio: Median Overall Survival Unreached, Lymphopenia Reversed In Recurrent Glioblastoma On Anktiva And CAR-NK Chemo-Free TherapyJan 23 (Reuters) - Immunitybio Inc IBRX.O:IMMUNITYBIO REPOR","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IBRX":"ImmunityBio, Inc."},"translate_title":"BRIEF-ImmunityBio：接受Anktiva和CAR-NK免化疗治疗的复发性胶质母细胞瘤未达到中位总生存期，淋巴细胞减少症逆转","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":0.9},"content_text":"BRIEF-ImmunityBio: Median Overall Survival Unreached, Lymphopenia Reversed In Recurrent Glioblastoma On Anktiva And CAR-NK Chemo-Free TherapyJan 23 (Reuters) - Immunitybio Inc IBRX.O:IMMUNITYBIO REPORTS MEDIAN OVERALL SURVIVAL NOT YET REACHED AND LYMPHOPENIA REVERSED IN RECURRENT GLIOBLASTOMA PATIENTS RECEIVING ANKTIVA® PLUS CAR-NK, CHEMO-FREE THERAPYIMMUNITYBIO INC: THREE PARTICIPANTS EXPERIENCED SERIOUS ADVERSE EVENTS SUSPECTED TO BE RELATED TO EXPERIMENTAL THERAPYIMMUNITYBIO INC: TREATMENT REGIMEN DEMONSTRATED A MANAGEABLE SAFETY PROFILESource text: ID:nBw95Lpc6aFurther company coverage: IBRX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605785472","isCrawlerRequest":true}